MX2009011642A - Compuestos y metodos para potenciar la solubilidad de florfenicol y antibioticos estructuralmente relacionados utilizando ciclodextrinas. - Google Patents
Compuestos y metodos para potenciar la solubilidad de florfenicol y antibioticos estructuralmente relacionados utilizando ciclodextrinas.Info
- Publication number
- MX2009011642A MX2009011642A MX2009011642A MX2009011642A MX2009011642A MX 2009011642 A MX2009011642 A MX 2009011642A MX 2009011642 A MX2009011642 A MX 2009011642A MX 2009011642 A MX2009011642 A MX 2009011642A MX 2009011642 A MX2009011642 A MX 2009011642A
- Authority
- MX
- Mexico
- Prior art keywords
- ffc
- florfenicol
- cyclodextrins
- structurally
- compounds
- Prior art date
Links
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 title abstract 6
- 229960003760 florfenicol Drugs 0.000 title abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 3
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 229940088710 antibiotic agent Drugs 0.000 title abstract 2
- 229940097362 cyclodextrins Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 230000009918 complex formation Effects 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 239000003651 drinking water Substances 0.000 abstract 1
- 235000020188 drinking water Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000144977 poultry Species 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91437607P | 2007-04-27 | 2007-04-27 | |
| PCT/US2008/005225 WO2008133901A1 (en) | 2007-04-27 | 2008-04-23 | Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011642A true MX2009011642A (es) | 2010-01-29 |
Family
ID=39619330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011642A MX2009011642A (es) | 2007-04-27 | 2008-04-23 | Compuestos y metodos para potenciar la solubilidad de florfenicol y antibioticos estructuralmente relacionados utilizando ciclodextrinas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090062397A1 (enExample) |
| EP (1) | EP2150245A1 (enExample) |
| JP (1) | JP2010525059A (enExample) |
| KR (1) | KR20100028537A (enExample) |
| CN (1) | CN101686956A (enExample) |
| AR (1) | AR066265A1 (enExample) |
| BR (1) | BRPI0810601A2 (enExample) |
| CA (1) | CA2685264A1 (enExample) |
| CL (1) | CL2008001194A1 (enExample) |
| MX (1) | MX2009011642A (enExample) |
| PE (1) | PE20090234A1 (enExample) |
| RU (1) | RU2009143731A (enExample) |
| TW (1) | TW200908955A (enExample) |
| WO (1) | WO2008133901A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY146351A (en) | 2003-05-29 | 2012-08-15 | Schering Plough Ltd | Compositions for treating infection in cattle and swine |
| CN101600686A (zh) * | 2006-12-13 | 2009-12-09 | 先灵-普劳有限公司 | 氯霉素、甲砜霉素及其类似物的水溶性前药 |
| GB2451811A (en) * | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
| JP2011529895A (ja) * | 2008-07-30 | 2011-12-15 | インターベツト・インターナシヨナル・ベー・ベー | フロルフェニコール中間体として有用なオキサゾリン保護アミノジオール化合物を調製する方法 |
| JP5826473B2 (ja) * | 2010-09-16 | 2015-12-02 | 協和発酵バイオ株式会社 | 直打用高単位グルコサミン顆粒 |
| CN102160854A (zh) * | 2011-04-15 | 2011-08-24 | 广东养宝生物制药有限公司 | 一种包合环糊精的氟苯尼考速释型水溶性粉末制剂及其制备方法 |
| CN102688197A (zh) * | 2012-06-07 | 2012-09-26 | 湖州爱宝莱动物药业有限公司 | 一种氟苯尼考水溶颗粒及其制备方法 |
| CN102813627A (zh) * | 2012-09-19 | 2012-12-12 | 上海同仁药业有限公司 | 一种氟苯尼考可溶性粉剂的制备方法 |
| CN104667291A (zh) * | 2013-12-03 | 2015-06-03 | 中牧实业股份有限公司黄冈动物药品厂 | 一种改进的氟苯尼考包合物的制备方法 |
| CN104800167B (zh) * | 2015-04-22 | 2018-04-10 | 河南牧翔动物药业有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
| CN105055319B (zh) * | 2015-07-22 | 2018-04-10 | 浙江大飞龙动物保健品有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
| CN105079818B (zh) * | 2015-08-31 | 2018-04-20 | 王玉万 | 用乙酰胺和环糊精制备氟苯尼考可溶性粉 |
| CN105477642B (zh) * | 2015-12-15 | 2019-08-06 | 中牧南京动物药业有限公司 | 一种高生物利用度的氟苯尼考组合物及其制备方法 |
| CN106177983A (zh) * | 2016-08-03 | 2016-12-07 | 佛山科学技术学院 | 一种氟苯尼考‑β‑环糊精包合物及其制备方法 |
| CN107519135A (zh) * | 2017-09-30 | 2017-12-29 | 中牧实业股份有限公司黄冈动物药品厂 | 一种高水溶型氟苯尼考粉的制备方法 |
| CN109602916A (zh) * | 2018-12-13 | 2019-04-12 | 广东温氏大华农生物科技有限公司 | 一种氟苯尼考包合物及其制备方法 |
| CN111374949A (zh) * | 2018-12-29 | 2020-07-07 | 西安市昌盛动物保健品有限公司 | 一种氟苯尼考可溶性粉或溶液的制备工艺 |
| CN110279664B (zh) * | 2019-07-30 | 2021-09-03 | 四川农业大学 | 一种氟苯尼考包合物冻干粉针剂及其制备方法 |
| CN112535663A (zh) * | 2019-09-23 | 2021-03-23 | 江西邦诚动物药业有限公司 | 一种速溶固体分散氟苯尼考粉及其制备方法 |
| CN110787131B (zh) * | 2019-12-13 | 2022-04-01 | 河北远征药业有限公司 | 一种氟苯尼考可溶性粉制剂的制备方法 |
| CN112190551A (zh) * | 2020-11-20 | 2021-01-08 | 湖北龙翔药业科技股份有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
| CN112675315A (zh) * | 2021-01-05 | 2021-04-20 | 佛山科学技术学院 | 一种γ-环糊精-替米考星包合物及其制备方法和应用 |
| CN112716902B (zh) * | 2021-02-04 | 2021-10-12 | 广州市和生堂动物药业有限公司 | 一种氟苯尼考粉及其制备方法 |
| CN112641730A (zh) * | 2021-02-19 | 2021-04-13 | 山东鲁抗舍里乐药业有限公司高新区分公司 | 一种可溶氟苯尼考粉的制备方法 |
| CN113230233A (zh) * | 2021-05-14 | 2021-08-10 | 中国农业科学院兰州畜牧与兽药研究所 | 一种氟苯尼考固体分散包合微囊及其制备方法与应用 |
| CN114272213B (zh) * | 2021-12-28 | 2023-10-10 | 厦门惠盈动物药业有限公司 | 一种氟苯尼考粉及其制备方法 |
| CN114209656B (zh) * | 2021-12-31 | 2023-08-01 | 浙江金朗博药业有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
| CN119385937B (zh) * | 2024-11-20 | 2025-07-15 | 山东金瑞生物科技有限公司 | 一种兽用氟苯尼考溶液及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES488154A0 (es) * | 1979-02-05 | 1981-04-16 | Schering Corp | Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol |
| IT1173213B (it) * | 1984-02-03 | 1987-06-18 | Zambon Spa | Procedimento per fluorurare alcuni derivati dall'1l-fenil-2-ammino-1,3-propandiolo e loro intermedi |
| US5105009A (en) * | 1983-06-02 | 1992-04-14 | Zambon S.P.A. | Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives |
| US5332835A (en) * | 1984-02-03 | 1994-07-26 | Zambon S.P.A. | Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process |
| US4582918A (en) * | 1984-09-19 | 1986-04-15 | Schering Corporation | Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols |
| US4973750A (en) * | 1984-09-19 | 1990-11-27 | Schering Corporation | Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols |
| US5227494A (en) * | 1988-09-14 | 1993-07-13 | Schering Corporation | Process for preparing oxazoline compounds |
| US4876352A (en) * | 1988-09-14 | 1989-10-24 | Schering Corporation | Pressurized fluorination of hydroxy alkyl groups |
| EP0443381B2 (en) * | 1990-02-14 | 1997-10-22 | Takeda Chemical Industries, Ltd. | Effervescent composition, its production and use |
| NZ250394A (en) * | 1990-10-25 | 1994-10-26 | Schering Corp | Fluorinated and hydroxylated oxazoline compounds |
| US5352832A (en) * | 1992-12-18 | 1994-10-04 | Schering Corporation | Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates |
| US5663361A (en) * | 1996-08-19 | 1997-09-02 | Schering Corporation | Process for preparing intermediates to florfenicol |
| GB0205253D0 (en) * | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
| US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
| CN1459282A (zh) * | 2003-05-29 | 2003-12-03 | 季华 | 水溶性氟苯尼考的生产方法 |
-
2008
- 2008-04-23 KR KR1020097024467A patent/KR20100028537A/ko not_active Withdrawn
- 2008-04-23 CA CA002685264A patent/CA2685264A1/en not_active Abandoned
- 2008-04-23 CN CN200880021603A patent/CN101686956A/zh active Pending
- 2008-04-23 MX MX2009011642A patent/MX2009011642A/es not_active Application Discontinuation
- 2008-04-23 EP EP08743209A patent/EP2150245A1/en not_active Withdrawn
- 2008-04-23 WO PCT/US2008/005225 patent/WO2008133901A1/en not_active Ceased
- 2008-04-23 PE PE2008000695A patent/PE20090234A1/es not_active Application Discontinuation
- 2008-04-23 BR BRPI0810601-0A2A patent/BRPI0810601A2/pt not_active IP Right Cessation
- 2008-04-23 JP JP2010506241A patent/JP2010525059A/ja not_active Withdrawn
- 2008-04-23 AR ARP080101709A patent/AR066265A1/es unknown
- 2008-04-23 US US12/108,032 patent/US20090062397A1/en not_active Abandoned
- 2008-04-23 RU RU2009143731/15A patent/RU2009143731A/ru not_active Application Discontinuation
- 2008-04-24 CL CL2008001194A patent/CL2008001194A1/es unknown
- 2008-04-24 TW TW097115132A patent/TW200908955A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200908955A (en) | 2009-03-01 |
| WO2008133901A1 (en) | 2008-11-06 |
| JP2010525059A (ja) | 2010-07-22 |
| KR20100028537A (ko) | 2010-03-12 |
| US20090062397A1 (en) | 2009-03-05 |
| RU2009143731A (ru) | 2011-06-10 |
| EP2150245A1 (en) | 2010-02-10 |
| PE20090234A1 (es) | 2009-04-02 |
| CA2685264A1 (en) | 2008-11-06 |
| CL2008001194A1 (es) | 2008-11-03 |
| CN101686956A (zh) | 2010-03-31 |
| AR066265A1 (es) | 2009-08-05 |
| BRPI0810601A2 (pt) | 2014-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011642A (es) | Compuestos y metodos para potenciar la solubilidad de florfenicol y antibioticos estructuralmente relacionados utilizando ciclodextrinas. | |
| Soni et al. | Solubilization of Poorly Water Soluble Drug Using Mixed Solvency Approach for Aqueous Injection. | |
| CR6654A (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco | |
| BRPI0706676B8 (pt) | uso de uma solução aquosa com potencial de oxirredução | |
| AR053737A1 (es) | Formulacion pediatrica de topiramato | |
| EA201170020A1 (ru) | Пегилированные соединения инсулина лизпро | |
| CY1122081T1 (el) | Διαλυματα τα οποια περιλαμβανουν πολυαιθυλενογλυκολη και ηλεκτρολυτες | |
| NZ709704A (en) | Protein formulations and methods of making same | |
| BR112012025047A2 (pt) | formulações líquidas estabilizadas | |
| ECSP045140A (es) | Formulaciones farmacéuticas derivadas del platino | |
| BRPI0416613A (pt) | composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão | |
| CY1115150T1 (el) | Βοηθηματα διαλυτοποιησης για τη χορηγηση πεπτιδιων απο το στομα, τα οποια περιεχουν διγουανιδη | |
| MX389346B (es) | Formulaciones de anticuerpos monoclonales de alta concentración. | |
| MX391566B (es) | Dispositivos y métodos para administración y mezcla de fármaco, y entrenamiento de técnicas apropiadas para ello. | |
| BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
| JP2016505576A5 (enExample) | ||
| PE20210413A1 (es) | Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad | |
| PL2397510T3 (pl) | Wysoko stężone granulowane dodatki do polimerów w postaci koncentratów | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| Patel et al. | Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo | |
| EA201070194A1 (ru) | Стабильная жидкая фармацевтическая композиция на основе тразодона | |
| NO20082848L (no) | Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre | |
| PE20090476A1 (es) | Soluciones farmaceuticas | |
| Dinakaran et al. | Pharmacokinetics of tolfenamic acid following two oral dose levels in buffalo calves. | |
| Ivaturi et al. | Enhanced permeation of methotrexate in vitro by ion pair formation with L-arginine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |